Search Results - target

20 Results Sort By:
Human Brain Proteins with Evidence Consistent with Causality of Alzheimer’s and Depression
Application Research and therapeutic targets for Alzheimer’s disease, depression, and other neurological conditions mediated by protein expression in the brain. Key Benefits These findings can be utilized as a research tool to better understand the genetic basis of Alzheimer’s disease. Can also be utilized to develop therapeutics for...
Published: 8/22/2024   |   Inventor(s): Aliza Wingo, Thomas Wingo, Yue Liu, Allan Levey, Nicholas Seyfried, Duc Duong
Keywords(s): Neuroscience/Pain, Target
Category(s): TechPub Algolia > Research Tools, TechPub Algolia > Therapeutics
EF-Tu Targeting Antibody for Infection Treatment
Application Therapeutic monoclonal antibodies directed to Elongation Factor-Tu (EF-Tu) for the treatment of infections. Key Benefits An antibody that targets the protein EF-Tu, which is present on many types of bacteria involved in life-threatening infections. A research-grade antibody has been developed with animal data showing the ability to...
Published: 7/30/2024   |   Inventor(s): Joanna Goldberg, Dina Moustafa
Keywords(s): Microbiology/Infectious Diseases, Target, Vaccine
Category(s): TechPub Algolia > Vaccines, TechPub Algolia > Therapeutics
A Novel Virus-Based Expression System
The present invention is related to a recombinant viral vector for vaccines. Currently available poxvirus vectors for humans and other animals exhibit suboptimal expression of recombinant gene(s) and high expression of vector proteins which causes weak immunogenicity and high anti-vector immune response. The present novel virus-based expression vectors...
Published: 7/25/2024   |   Inventor(s): Linda Wyatt, Bernard Moss
Keywords(s): Expression, Gene, GENES, High, LOW, Non-Replicating, System, TARGET, vaccinia, Vector, virus, VJXXXX, VKXXXX, VLXXXX, VOXXXX, WAXXXX, WIXXXX, WNXXXX, XEXXXX, YAXXXX, YBXXXX, YFXXXX
Category(s): Collaboration Sought > Collaboration, Application > Research Materials, Application > Diagnostics, Application > Vaccines, TherapeuticArea > Infectious Disease, Application > Consumer Products, Application > Therapeutics
Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology
Due to the disorganized nature of blood vessels that run through tumors, chemotherapeutic agents often fail to penetrate tumors and kill cancer cells at the tumor’s center. This can lead to ineffective chemotherapeutic treatments, because tumors can quickly grow back if the entire tumor is not destroyed. NIH researchers have developed a therapeutic...
Published: 7/25/2024   |   Inventor(s): Stephen Leppla, Shihui Liu, Thomas Bugge, Diane Peters, Jie Liu, Alexander Wein, Kuang-Hua Chen, Christopher Bachran, Damilola Phillips, Henning Hansen, Sarah Arnett, Clinton Leysath
Keywords(s): Against, AMOUNTS, Anthrax, AnthraxToxins, ANTIGEN, B, CA1BXX, CB1AXX, CB1BXX, CB1XXX, CB3CXX, CBXXXX, Cells, Cell-Surface, CMG2, COMPLEMENTARY, CONTAIN, Containing, CXXXXX, Cytolethal, Distending, EFFICACY, Efficient, ENGINEERED, exclusively, Exploiting, FELINE, FELINE Leukemia, FORM, Fusion, fusion proteins, Having, High, IC2-PA, Identifying, Improved, Leppla, Listed LPM McCue as of 4/15/2015, MARKER, Metallo..., MULTIMERIC, Mutated, Nature, Octamers, Patent Category - Biotechnology, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Protective, Protein, proteins, SOLID, SPECIFICALLY, Specificity, Strong, TARGET, Targeting, That, THERAPY, toxin, TOXINS, tumor, Types, UAXXXX, VARIANTS, VASCULATURE, VETERINARY
Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Diagnostics, TherapeuticArea > Rare / Neglected Diseases
Antimalarial Inhibitors that Target the Plasmodial Surface Anion Channel (PSAC) Protein and Development of the PSAC Protein as Vaccine Targets
There are two related technologies, the first being small molecule inhibitors of the malarial plasmodial surface anion channel (PSAC) and the second being the PSAC protein itself as a vaccine candidate. The PSAC protein is produced by the malaria parasite within host erythrocytes and is crucial for mediating nutrient uptake. In vitro data show that...
Published: 7/25/2024   |   Inventor(s): Sanjay Desai
Keywords(s): Anion, ANTIMALARIAL, CHANNEL, DC2XXX, DCXXXX, DXXXXX, Plasmodial, Surface, TARGET, THERAPY
Category(s): Collaboration Sought > Collaboration, Application > Vaccines, TherapeuticArea > Infectious Disease
Methods and Devices for Transcatheter Cerclage Annuloplasty
The invention relates to techniques and devices for cardiovascular valve repair, particularly annuloplasty techniques and devices in which tensioning elements are positioned to treat regurgitation of the mitral valve or tricuspid valve. More specifically, the technology pertains to a new device for myocardial septal traversal ("cerclage reentry") that...
Published: 7/25/2024   |   Inventor(s): Robert Lederman
Keywords(s): AB3FXX, ABXXXX, Annuloplasty, AXXXXX, CAPTURE, Cerclage, DEVICE, Expandable, Mesh, Patent Category - Mech/Elect/Soft, TARGET, Transcatheter
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing
Modulation of Leucine-rich Repeats and Calponin Homology Domain-containing Protein 4 (Lrch4) Activity for Therapeutic Applications
NIH Inventors have recently discovered a novel Leucine-rich repeat and calponin homology domain-containing protein 4 (Lrch4) in a proteomic screen of the plasma membrane of lipopolysaccharide (LPS)-exposed macrophages. Expression data by RT-PCR revealed that all Lrch family members (1-4) are expressed in macrophages, but only Lrch4 was recruited into...
Published: 7/25/2024   |   Inventor(s): Michael Fessler
Keywords(s): CB6XXX, CBXXXX, CXXXXX, DISEASES, GB1XXX, GBXXXX, GXXXXX, IB3XXX, IBXXXX, INFLAMMATORY, IXXXXX, Lrch4, Sepsis, TARGET, therapeutic
Category(s): Collaboration Sought > Collaboration, Application > Research Materials, Application > Diagnostics, Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Immunology
A Predictive Marker and Treatment to Sensitize Multiple Myeloma Patients to Venetoclax (ABT-199)
Application A marker that predicts Venetoclax (ABT-199) sensitivity that can also be targeted with a drug to help multiple myeloma patients. Key Benefits Marker that predicts if venetoclax will be an effective treatment in multiple myeloma patients. A drug that targets venetoclax resistant multiple myeloma cells to improve treatment in patients. Market...
Published: 7/30/2024   |   Inventor(s): Malathy (mala) Shanmugam, Richa Bajpai
Keywords(s): Biologic, Biomarker, Oncology, Repurposed Drug, Target
Category(s): TechPub Algolia > Diagnostics
KRAS Mutant Protein-Protein Interaction Targets and Inhibitors for Cancer Therapy
Application Immunotherapeutic agent and biosensor for KRASG12V mutation in tumor cells. Key Benefits First in class, targeted immunotherapy for patients presented with KRASG12V mutation. Attenuates immune suppression associated with KRASG12V-positive cancers. Market Summary The KRASG12V mutation, representing 85% of all cancer mutations, is...
Published: 8/22/2024   |   Inventor(s): Haian Fu, Cong Tang, Xiulei Mo
Keywords(s): Enzyme/Protein, Immunology/Inflammation, Oncology, Target
Category(s): TechPub Algolia > Drug Discovery, TechPub Algolia > Therapeutics
Combination Therapy for Increasing Venetoclax Sensitivity in Multiple Myeloma
Application Marker and co-therapy that inhibits succinate dehydrogenase to increase patient response to venetoclax. Key Benefits Co-therapy increases MM sensitivity to venetoclax treatment. Identifies patients who will respond to venetoclax therapy. Market Summary Multiple Myeloma (MM) is a cancer of plasma cells responsible for making antibody...
Published: 7/30/2024   |   Inventor(s): Malathy (mala) Shanmugam, Richa Bajpai
Keywords(s): Biologic, Biomarker, Oncology, Rare/Orphan Diseases, Repurposed Drug, Target
Category(s): TechPub Algolia > Diagnostics, TechPub Algolia > Therapeutics, TechPub Algolia > Drug Discovery
1 2